Literature DB >> 24038279

Neurological deficits caused by tissue hypoxia in neuroinflammatory disease.

Andrew L Davies1, Roshni A Desai, Peter S Bloomfield, Peter R McIntosh, Katie J Chapple, Christopher Linington, Richard Fairless, Ricarda Diem, Marianne Kasti, Michael P Murphy, Kenneth J Smith.   

Abstract

OBJECTIVE: To explore the presence and consequences of tissue hypoxia in experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS).
METHODS: EAE was induced in Dark Agouti rats by immunization with recombinant myelin oligodendrocyte glycoprotein and adjuvant. Tissue hypoxia was assessed in vivo using 2 independent methods: an immunohistochemical probe administered intravenously, and insertion of a physical, oxygen-sensitive probe into the spinal cord. Indirect markers of tissue hypoxia (eg, expression of hypoxia-inducible factor-1α [HIF-1α], vessel diameter, and number of vessels) were also assessed. The effects of brief (1 hour) and continued (7 days) normobaric oxygen treatment on function were evaluated in conjunction with other treatments, namely administration of a mitochondrially targeted antioxidant (MitoQ) and inhibition of inducible nitric oxide synthase (1400W).
RESULTS: Observed neurological deficits were quantitatively, temporally, and spatially correlated with spinal white and gray matter hypoxia. The tissue expression of HIF-1α also correlated with loss of function. Spinal microvessels became enlarged during the hypoxic period, and their number increased at relapse. Notably, oxygen administration significantly restored function within 1 hour, with improvement persisting at least 1 week with continuous oxygen treatment. MitoQ and 1400W also caused a small but significant improvement.
INTERPRETATION: We present chemical, physical, immunohistochemical, and therapeutic evidence that functional deficits caused by neuroinflammation can arise from tissue hypoxia, consistent with an energy crisis in inflamed central nervous system tissue. The neurological deficit was closely correlated with spinal white and gray matter hypoxia. This realization may indicate new avenues for therapy of neuroinflammatory diseases such as MS.
© 2013 American Neurological Association.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24038279     DOI: 10.1002/ana.24006

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  58 in total

1.  Deletion of mitochondrial anchoring protects dysmyelinating shiverer: implications for progressive MS.

Authors:  Dinesh C Joshi; Chuan-Li Zhang; Tien-Min Lin; Anchal Gusain; Melissa G Harris; Esther Tree; Yewin Yin; Connie Wu; Zu-Hang Sheng; Robert J Dempsey; Zsuzsanna Fabry; Shing Yan Chiu
Journal:  J Neurosci       Date:  2015-04-01       Impact factor: 6.167

2.  Veins in plaques of multiple sclerosis patients - a longitudinal magnetic resonance imaging study at 7 Tesla.

Authors:  Assunta Dal-Bianco; Simon Hametner; Günther Grabner; Melanie Schernthaner; Claudia Kronnerwetter; Andreas Reitner; Clemens Vass; Karl Kircher; Eduard Auff; Fritz Leutmezer; Karl Vass; Siegfried Trattnig
Journal:  Eur Radiol       Date:  2015-04-23       Impact factor: 5.315

Review 3.  The neuropathology and cerebrovascular mechanisms of dementia.

Authors:  Limor Raz; Janice Knoefel; Kiran Bhaskar
Journal:  J Cereb Blood Flow Metab       Date:  2016-01       Impact factor: 6.200

4.  The Niels Lassen Award Session and Oral Sessions.

Authors: 
Journal:  J Cereb Blood Flow Metab       Date:  2017-04       Impact factor: 6.200

Review 5.  Pharmacological Approaches to the Management of Secondary Progressive Multiple Sclerosis.

Authors:  A Nandoskar; J Raffel; A S Scalfari; T Friede; R S Nicholas
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

Review 6.  The role of glial-neuronal metabolic cooperation in modulating progression of multiple sclerosis and neuropathic pain.

Authors:  Rachel R Robinson; Alina K Dietz; Asif M Maroof; Reto Asmis; Thomas G Forsthuber
Journal:  Immunotherapy       Date:  2019-02       Impact factor: 4.196

Review 7.  Thyroid Hormone Signaling in Oligodendrocytes: from Extracellular Transport to Intracellular Signal.

Authors:  Jae Young Lee; Steven Petratos
Journal:  Mol Neurobiol       Date:  2016-07-18       Impact factor: 5.590

Review 8.  Therapeutic Advances and Future Prospects in Progressive Forms of Multiple Sclerosis.

Authors:  Afsaneh Shirani; Darin T Okuda; Olaf Stüve
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 9.  Nogo-A Antibodies for Progressive Multiple Sclerosis.

Authors:  Benjamin V Ineichen; Patricia S Plattner; Nicolas Good; Roland Martin; Michael Linnebank; Martin E Schwab
Journal:  CNS Drugs       Date:  2017-03       Impact factor: 5.749

Review 10.  Understanding the role of the perivascular space in cerebral small vessel disease.

Authors:  Rosalind Brown; Helene Benveniste; Sandra E Black; Serge Charpak; Martin Dichgans; Anne Joutel; Maiken Nedergaard; Kenneth J Smith; Berislav V Zlokovic; Joanna M Wardlaw
Journal:  Cardiovasc Res       Date:  2018-09-01       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.